Biofrontera Inc. Operating Lease Cost
Biofrontera Inc. (BFRI) reported Operating Lease Cost of $200.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-13
- Biofrontera Inc. operating lease, cost for the quarter ending 2026-06-30 was $200.00K, a 0.00% change year-over-year.
- Biofrontera Inc. operating lease, cost for the quarter ending 2026-03-31 was $200.00K, a 0.00% change year-over-year.
- Biofrontera Inc. operating lease, cost for the quarter ending 2025-06-30 was $200.00K.
- Biofrontera Inc. operating lease, cost for the quarter ending 2025-03-31 was $200.00K.
- Biofrontera Inc. operating lease, cost for fiscal 2025 was $790.00K, a 3.19% decline from fiscal 2024.
- Biofrontera Inc. operating lease, cost for fiscal 2024 was $816.00K, a 26.71% increase from fiscal 2023.
- Biofrontera Inc. operating lease, cost for fiscal 2023 was $644.00K, a 14.36% decline from fiscal 2022.
- Biofrontera Inc. operating lease, cost for fiscal 2022 was $752.00K.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $200.00K 10-Q · filed 2026-08-13 | $400.00K 10-Q · filed 2026-08-13 | ||
| 2026-03-31 | $200.00K 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | $790.00K 10-K · filed 2026-03-19 | |||
| 2025-06-30 | $200.00K 10-Q · filed 2026-08-13 | $400.00K 10-Q · filed 2026-08-13 | ||
| 2025-03-31 | $200.00K 10-Q · filed 2026-05-14 | |||
| 2024-12-31 | $816.00K 10-K · filed 2026-03-19 | |||
| 2023-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $342.00K derived: sum of 2 quarters · filed 2025-03-20 | $485.00K derived: sum of 3 quarters · filed 2025-03-20 | $644.00K 10-K · filed 2025-03-20 |
| 2023-09-30 | $142.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $285.00K derived: sum of 2 quarters · filed 2023-11-09 | $444.00K 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $143.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $302.00K 10-Q · filed 2023-08-11 | ||
| 2023-03-31 | $159.00K 10-Q · filed 2023-05-12 | |||
| 2022-12-31 | $752.00K 10-K · filed 2024-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B |